MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing targeted local delivery therapies for inherited and common conditions, including radiation-induced xerostomia, Parkinson’s disease, and AIPL1-associated retinal dystrophy. The company operates manufacturing facilities in London, United Kingdom, and Shannon, Ireland, producing GMP-compliant viral vectors and plasmid DNA for internal clinical programs and third-party supply. Its pipeline includes botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa and AAV2-hAQP1, supported by a riboswitch platform that enables dose-responsive control of gene expression via oral small molecules. This technology targets the in vivo delivery of metabolic peptides such as GLP-1, GIP, glucagon, amylin, PYY, and leptin, as well as cell therapies for oncology and autoimmune diseases. MeiraGTx maintains a supply agreement with Johnson & Johnson Innovative Medicine for the commercial production of the RPGR product, following the sale of related assets in 2023. The company utilizes in-house capabilities for viral vector optimization, capsid design, and quality control to support its clinical development programs.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage meiragtx.com
Sector Healthcare IR page investors.meiragtx.com
Tags
gene therapy, viral vectors, retinal dystrophy, parkinson's disease, radiation-induced xerostomia, riboswitch technology, metabolic peptides, glp-1, cell therapy, oncology, autoimmune diseases, gmp manufacturing, botaretigene sparoparvovec, bota-vec, AAV2-hAQP1, MeiraGTx UK II Limited, MeiraGTx Limited, Johnson & Johnson Innovative Medicine, Janssen Pharmaceuticals Inc., UCL Business Plc, UCL Business Ltd., RPGR Product, GIP, glucagon, amylin, PYY, leptin, CAR-T
Press page meiragtx.com/latest-news

Metrics

Valuation  
Market cap $ 824.884M
Market cap (USD) $ 824.884M
P/E 10.56
PEG —
P/BV 3.83
P/S 10.13
P/OCF 608.77
P/FCF -275.97
Dividend yield —
Turnover / mcap —
Returns  
ROE 1,971.4%
ROI -166.6%
ROIC -115.9%
Profit margin -140.3%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 23
Quality score -41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 81.391M 33.279M 14.017M 15.92M 37.701M 15.563M 13.292M — —
Net profit -114.201M -147.791M -84.027M -129.615M -79.561M -57.992M -54.746M -82.866M -31.045M
Free cash flow -50.185M -109.45M -125.539M -118.061M -56.881M -84.891M 11.064M -70.146M -28.591M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 7.95 6.09 7.02 6.52 23.74 15.14 20.02 9.64 —
Price performance 12m 0.31 -0.13 0.08 -0.73 0.57 -0.24 1.08 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — 21.3M 10.1M 707,000 3M
↳ YoY growth -52.5% -93.0% +324.3%
Lease liabilities (USD) — — 34,296 23.2M 22.2M 23.7M 21.2M 17.1M 11.6M 14.3M
Cash and deposits (USD) 17.9M 8.55M 68.1M 227M 210M 138M 116M 130M 104M 65.9M
Intangible assets (USD) — — — 0.00 2.12M 1.79M 1.34M 1.12M 821,000 578,000
Right-of-use assets (USD) — — — 21.9M 21.5M 22.8M 20.1M 15.9M 10.6M 12.9M
Cash flow detail
Operating cash flow (USD) — -18.1M -58.9M 20M -64M -10.5M -73.1M -105M -104M -46.4M
Purchases of property, plant and equipment (USD) — -10.5M -11.3M -8.98M -20.9M -46.4M -45M -20.2M -4.96M -3.83M
Purchases of intangible assets (USD) — — — — -2.13M — — — — —
Change in payables (cash effect) (USD) — 4.73M -2.12M -8,681 1.57M 13.3M 3.74M 2.33M 10.7M -12.3M
Interest paid (cash effect) (USD) — -20,894 -34,546 -1,462 -3,134 -139,000 -329,000 -13.1M -12M -11M
Income taxes paid (cash effect) (USD) — — — — — — — — 0.00 0.00
Share-based compensation (USD) — 2.96M 17.9M 15.9M 18.4M 20.8M 28.6M 27.7M 25.2M 22.1M
Free cash flow (OCF - PPE - intangibles) (USD) — -28.6M -70.1M 11.1M -87M -56.9M -118M -126M -109M -50.2M
Income detail
Research and development expense (USD) — 22.4M 33.6M 24.9M 33.9M 67.1M 85.7M 104M 119M 130M
↳ 5y CAGR +30.8% +25.3% +36.9% +30.8%
Total comprehensive income (USD) — -32.4M -80.5M -56.8M -61.1M -77.3M -121M -91.5M -150M -108M
Comprehensive income to owners (USD) — -32.4M -80.5M -56.8M -61.1M -77.3M -121M -91.5M -150M -108M
Reported Aug 8, 2018 Mar 26, 2019 Mar 11, 2020 Mar 11, 2021 Mar 11, 2021 Mar 10, 2022 Aug 10, 2023 Mar 15, 2024 Mar 30, 2026 Mar 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

●Submission of Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) expected in December 2026

●Submission of full Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bota-vec expected in the first quarter of 2027

●12-month data readout in pivotal Phase 2 AQUAx2 study of AAV2-hAQP1 for the treatment of radiation-induced xerostomia (RIX) mid-2027

●Upcoming oral presentation at ObesityWeek highlights AAV-BDNF program for the treatment of MC4R/BDNF genetic obesity (severe early-onset syndromic obesity)

●Strengthened leadership with the appointment of John Knighton as Executive Vice President of Global Manufacturing and Supply Chain and Alan M. Sebulsky to the Board of Directors

LONDON and NEW YORK, November 12, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2026, and provided a corporate update.

October 27, 2026

Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms

LONDON and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit three posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress, which is being held from October 27-30, 2026, in Hamburg, Germany and one poster at the Network of Excellence for ALS (NEALS) Annual Meeting which is being held from October 27-30, 2026, in Clearwater, FL.

The posters will be available on the Posters and Publications page of the Company’s website after their respective conference presentation times.

The details of the poster presentations are as follows:

ESGCT Annual Congress:

**Poster Number:**P0096 Abstract Title: A commercial in-vitro biological activity potency assay for AAV-AQP1 treatment of Xerostomia Poster Session: Thursday, October 29, from 14:00 to 16:00 CET Abstract: Xerostomia, resulting from ionizing radiation treatment for head and neck cancer or Sjögren’s syndrome is associated with irreversible salivary gland damage, oral dryness, impaired chewing and swallowing, and reduced quality of life. MeiraGTx’s rAAV-AQP1 gene therapy product is being developed to restore localized water movement in damaged salivary glands through expression of human aquaporin 1 (hAQP1), a constitutively active membrane water channel that promotes osmotic water transport.

This study describes the development and optimization of a biological activity potency assay to quantify the water movement in a surrogate cell line after treatment with our product rAAV-AQP1 via fluorescence-based plate reader. The assay is based on calcein quenching, in which fluorescently labelled cells are exposed to a hyperosmotic sugar gradient, resulting in a cell volume change by water efflux. The rate of water transport reaction can be calculated by measuring and analyzing the changes in fluorescence. Compared with the previously used methods, the plate reader approach provides a rapid kinetic readout and enables quantitative assessment with improved throughput, precision, and robustness.

Preliminary optimization studies identified T98G cells as the most suitable assay model due to lower endogenous AQP1 activity, broad linear range, and compatibility with complementary expression studies, despite higher transducibility observed in HeLa cells. Samples transduced with rAAV-AQP1 demonstrated a significantly faster reduction in cell volume compared with untransduced controls, consistent with increased AQP1-mediated water transport. Observed rate constants remained consistent across different sugar concentrations at equivalent multiplicities of infection, supporting assay robustness across osmotic conditions. Intra-assay variability remained below 20% CV throughout assay evaluation. The assay is being validated for key analytical performance characteristics to ICH Q2(R2) standards including linearity, precision, specificity, robustness, and stability.

Together, this work establishes a scalable and biologically relevant in-vitro mode of action potency assay to support rAAV-AQP1 product development, Quality Control release and future commercial licensing.

**Poster Number:**P0099 **Abstract Title:**Denaturing size exclusion chromatography-MS for characterisation of AAV and assessment of CQAs **Poster Session:**Wednesday, October 28, from 13:30 to 15:30 CET Abstract: Adeno-associated virus (AAV) is a gene therapy vector composed of a single-stranded DNA genome (~4.7 kb) encapsulated within a protein capsid. The characterization of the viral proteins (VP1–VP3) forming the capsid is crucial for understanding potential alterations in stoichiometry and post-translational modifications (PTMs) which may occur during manufacturing. These changes can impact critical quality attributes (CQA’s) and critical process parameters (CPP’s) such as transduction efficiency, genome packaging and vector stability. At MeiraGTx, this is currently assessed using reverse-phase LC-MS; however, the shallow gradient employed limits separation of viral proteins. Capillary Electrophoresis–SDS (CE-SDS) is also used to assess VP stoichiometry, although it reveals a pre-peak hypothesized to arise from VP3 truncation during sample preparation. Denaturing size exclusion chromatography–MS (dSEC-MS) has emerged as a promising alternative assay that may improve viral protein separation while minimizing artefacts introduced during sample preparation.

This study describes the development of a dSEC-MS method for characterization of AAV drug product at MeiraGTx and its comparison with reverse-phase LC-MS. Buffer optimization was performed to achieve baseline separation of VP1/VP2/VP3 and improve analytical sensitivity. The results demonstrate that dSEC-MS provides improved resolution of viral proteins for AAV2, AAV5, and AAV8 relative to reverse-phase LC-MS while maintaining comparable deconvolution performance for identification of PTMs. The method also exhibited strong sensitivity and linearity. In addition, it was applied to characterize the CE-SDS pre-peak, confirming a cleavage site within the C-terminal region of capsid proteins. Furthermore, analysis of VP protein cross-linking via disulfide bonding revealed that VP3–VP3 disulfide formation is predominant during capsid assembly, suggesting that variations in disulfide bonding may influence AAV capsid stability.

Overall, dSEC-MS provides a more robust, artefact-reduced approach for AAV capsid protein analysis, enabling improved assessment of VP stoichiometry and structural heterogeneity. Its platform applicability across multiple serotypes supports its use as a valuable analytical tool in gene therapy process development and product characterization.

**Poster Number:**P0508 Abstract Title: AAV-NRF2 rescues RPE cell function and viability in human IPSC-derived and mouse models of oxidative stress Poster Session: Thursday, October 29, from 14:00 to 16:00 CET Abstract: Dry AMD accounts for 85-90% of all AMD cases with few therapeutic options available to patients. While a variety of environmental and genetic risk factors contribute to the onset of AMD, oxidative stress is a major underlying pathology of early AMD and its progression. Here we present evidence for the therapeutic efficacy of an AAV vector expressing NRF2 in IPSC-retinal pigmented epithelium (RPE) and a mouse model of oxidative stress.

NRF2 (nuclear factor erythroid 2-related factor 2) is a master transcription factor regulating cellular defense against oxidative stress by controlling the expression of over 250 antioxidant and detoxification genes. We have designed AAV vectors expressing NRF2 under the control of a ubiquitous CAG promoter or novel tissue-specific RPE (retinal pigmented epithelium) promoters and packaged them into engineered AAV capsids with high transduction efficiency in human RPE cells.

Mature IPSC-RPE cells treated with tert Butyl hydroperoxide (tBH), upregulate oxidative stress genes and undergo dose-dependent loss of function – quantified here by a reduction in trans epithelial resistance (TER) and internalization of bovine photoreceptor outer segments (POS). At high tBH doses, RPE undergo apoptosis.

Bulk RNAseq data show how AAV-NRF2 transduced RPE cells are able to mount a significantly stronger antioxidative stress response to tBH. As a result, NRF2 transduced RPE has significantly increased resilience with a complete rescue of viability, phagocytic function and barrier integrity (Trans-Epithelial Resistance; TER) following tBH doses which induce significant loss of function in non-transduced cells.

Our AAV-NRF2 vectors were also tested in a mouse model of dry AMD. Subretinal delivery of AAV-NRF2 did not induce any significant structural changes in the retina four weeks post treatment – indicating a clean safety profile. AAV-NRF2 significantly reduced sodium iodate induced RPE atrophy (F-actin staining) and completely prevented sodium iodate induced loss of electrophysiological responses in the retina.

Together, our results show that our AAV-NRF2 vectors have the ability to protect RPE from oxidative stress and as such show significant therapeutic potential for the treatment of dry AMD.

NEALS Annual Meeting:

**Poster Number:**53 **Abstract Title:**The Development and Optimization of AAV-mediated Gene Medicine as Potential ALS Therapeutics **Poster Session 1:**Wednesday, October 28, from 16:30 to 18:30 ET Abstract: Background: UPF1, a central regulator in nonsense-mediated RNA decay (NMD), and CNTFRa, a cytokine receptor enriched in skeletal muscle that is upregulated after denervating injuries, are therapeutic candidates that may be agnostic to ALS patients’ genetic background. Objective: MeiraGTx presents the development and optimization of AAV-hUPF1 and AAV-hCNTFRa, two pre-clinical gene therapies. Methods: We optimized the construct sequence to improve AAV packaging and increase expression to lower therapeutic dose requirements for clinical translation. We tested for efficacy in both in-vitro and in-vivo models of ALS. Results/Impact: For AAV-hUPF1, we reduced the size of the original construct by 1.5kb while improving therapeutic efficacy in both in vitro and in vivo models. The optimized AAV-hUPF1 effectively mitigated toxicity in TDP-43 and C9orf72 iNeuron models and restored function of neurons derived from patient at lower doses than used for the original. Mechanistically, UPF1 target engagement was confirmed in transduced C9orf72 patient-derived neurons by the downregulation of known NMD targets. In a FUS mouse model of ALS, optimized AAV-hUPF1 significantly improved motor neuron survival to levels comparable to wild-type controls at approximately 36% transduction.

For AAV-hCNTFRα, we implemented vector optimization that included unique combinations of ubiquitous and muscle-specific promoters, enhancers, and key 3’-UTR regulatory elements. We established effective in vitro transgene expression in HEK293T and C2C12 cells with our optimized constructs and demonstrated that CNTFRα is expressed in both the cell lysate and conditioned media, indicating both membrane-bound and soluble CNTFRα are present. We utilized IM injection of AAV-CNTFRα into the mouse gastrocnemius to establish in vivo protein expression, relative solubility, and biodistribution of locally administered AAV-hCNTFRα. Conclusion/Next Steps: Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS. We continue to develop both programs with additional efficacy validation and the development of biological activity assays to support the manufacturing of the AAV gene medicine.

About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-stage clinical programs. Each of these programs use local delivery of small doses resulting in disease modifying effects in both inherited and more common diseases, in the eye, radiation-induced xerostomia, and Parkinson’s disease. MeiraGTx uses its innovative technology in optimization of capsids, promoters and novel translational control elements to develop best in class, potent, safe viral vectors. MeiraGTx’s broad pipeline is supported by end-to-end in-house manufacturing. MeiraGTx has built the most comprehensive manufacturing capabilities in the industry, including two that are licensed for GMP viral vector production and a GMP QC facility with clinical and commercial licensure. In addition, MeiraGTx has developed a proprietary manufacturing platform process over 10 years based on more than 20 different viral vectors with leading yield and quality aspects and commercial readiness. Uniquely, MeiraGTx has developed a novel technology for in vivo delivery of any biologic therapeutic using oral small molecules. This transformative riboswitch gene regulation technology allows precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on the regulated in vivo delivery of metabolic peptides, including GLP-1, GIP, Glucagon, Amylin, PYY and Leptin, as well as cell therapy, CAR-T for liquid and solid tumors and autoimmune diseases, and additionally PNS targets addressing long term intractable pain. MeiraGTx has developed the technology to apply genetic medicine to common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.

September 23, 2026

LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.

Mr. Sebulsky is a veteran healthcare portfolio manager and biopharmaceutical investment analyst with more than 40 years of experience in public company investment, financial strategy, portfolio evaluation and growth, and board leadership. Mr. Sebulsky most recently served as Partner and Portfolio Manager at Adage Capital Management for the past 14 years, where he led a team overseeing a diversified biopharmaceutical portfolio with over $2 billion in assets. Prior to this, he founded Apothecary Capital, an asset management firm focused on investments across the healthcare and biopharmaceutical sectors. He reestablished Apothecary in April 2026 and currently serves as the Managing Member.

Mr. Sebulsky currently serves on the Board of Directors of Parabilis Medicines, Inc. and previously served on the Boards of Directors and Audit Committees for both Jazz Pharmaceuticals and Arrow International, two publicly traded healthcare companies, and on the boards of three private healthcare companies in which Apothecary Capital invested. In these roles, he worked closely with company leadership to advance portfolio, commercial and business strategy.

Mr. Sebulsky holds an M.S. in finance and a B.B.A. in finance and economics from the University of Wisconsin–Madison.

“We are delighted to welcome Alan to our Board of Directors,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “I have known Alan for 25 years and I have always had the highest respect for him both professionally and personally. His decades of investing in and working with biopharmaceutical companies brings a valuable perspective to the board which is particularly important as we continue to transform MeiraGTx into a commercial company.”

Keith Harris, Chairman of the Board of Directors of MeiraGTx, added, “I am pleased that Alan is joining our board. He brings an extensive wealth of knowledge of our sector and public company experience. We look forward to his invaluable assistance in helping the further growth of our Company.”

About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-stage clinical programs. Each of these programs use local delivery of small doses resulting in disease modifying effects in both inherited and more common diseases, in the eye, radiation-induced xerostomia, and Parkinson’s disease. MeiraGTx uses its innovative technology in optimization of capsids, promoters and novel translational control elements to develop best in class, potent, safe viral vectors. MeiraGTx’s broad pipeline is supported by end-to-end in-house manufacturing. MeiraGTx has built the most comprehensive manufacturing capabilities in the industry, including two that are licensed for GMP viral vector production and a GMP QC facility with clinical and commercial licensure. In addition, MeiraGTx has developed a proprietary manufacturing platform process over 10 years based on more than 20 different viral vectors with leading yield and quality aspects and commercial readiness. Uniquely, MeiraGTx has developed a novel technology for in vivo delivery of any biologic therapeutic using oral small molecules. This transformative riboswitch gene regulation technology allows precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on the regulated in vivo delivery of metabolic peptides, including GLP-1, GIP, Glucagon, Amylin, PYY and Leptin, as well as cell therapy, CAR-T for liquid and solid tumors and autoimmune diseases, and additionally PNS targets addressing long term intractable pain. MeiraGTx has developed the technology to apply genetic medicine to common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.

Prompts

MeiraGTx Holdings plc (ticker MGTX), listed in United States.

ETFs Holding MeiraGTx Holdings plc

ETF Weight in ETF Shares Market value As of
JSML 1.41% 434,668 $ 5.125M Jul 31, 2026
JSMD 0.35% 313,985 $ 3.702M Jul 31, 2026
ESSC 0.12% 3,786 $ 44.637K Jul 31, 2026
RESM 0.03% 82 $ 1,107.82 Jun 30, 2026
AVUQ 0.00% 285 $ 2,490.90 Nov 16, 2026